NASDAQ : ASPE

Aspen Neuroscience, Inc. — Financial statements

Healthcare · Biotechnology · United States

Overview · Financial statements · Key statistics · Dividends · Company profile · Price history · Reports

Financial statements

Income statement

Fiscal year January - December; amounts in USD.

TTMFY2025FY2024
Selling, General & Admin17.16M17.47M17.86M
Research & Development49.48M41.83M35.59M
Operating Expenses66.64M59.30M53.46M
Operating Income-66.64M-59.30M-53.46M
Interest & Investment Income2.60M1.79M4.40M
Other Non Operating Income (Expenses)-2.81M-4.54M504.00K
Pretax Income-66.84M-62.06M-48.56M
Net Income-66.84M-62.06M-48.56M
Net Income to Common-66.84M-62.06M-48.56M
Shares Outstanding (Basic)10.62M10.32M9.26M
Shares Outstanding (Diluted)10.62M10.32M9.26M
EPS (Basic)-6.29-6.01-5.24
EPS (Diluted)-6.29-6.01-5.24
Free Cash Flow-66.51M-62.54M-46.75M
Free Cash Flow Per Share-6.26-6.06-5.05
EBITDA-64.92M-57.67M-52.10M
D&A For EBITDA1.71M1.64M1.36M
EBIT-66.64M-59.30M-53.46M

Balance sheet

Fiscal year January - December; amounts in USD.

TTMFY2025FY2024
Cash & Equivalents21.29M82.10M15.22M
Short-Term Investments51.09M28.60M42.46M
Cash & Short-Term Investments72.38M110.70M57.68M
Prepaid Expenses2.22M1.69M1.91M
Total Current Assets74.59M112.39M59.59M
Property, Plant & Equipment29.32M27.43M23.14M
Long-Term Deferred Charges2.59M58.00K513.00K
Other Long-Term Assets2.83M2.84M1.47M
Total Assets110.28M143.66M90.21M
Accounts Payable5.54M2.64M853.00K
Accrued Expenses7.10M7.61M8.13M
Current Portion of Leases3.58M3.53M3.43M
Other Current Liabilities133.00K486.00K1.63M
Total Current Liabilities16.35M14.26M14.04M
Long-Term Leases6.19M7.67M10.40M
Other Long-Term Liabilities20.00K
Total Liabilities22.54M21.93M24.46M
Common Stock1.00K1.00K1.00K
Additional Paid-In Capital13.85M11.25M8.52M
Retained Earnings-264.89M-228.34M-166.28M
Comprehensive Income & Other-42.00K13.00K39.00K
Total Common Equity-251.07M-217.08M-157.73M
Shareholders' Equity87.73M121.73M65.75M
Total Liabilities & Equity110.28M143.66M90.21M
Total Debt9.77M11.20M13.83M
Net Cash (Debt)62.61M99.50M43.85M
Net Cash Per Share5.909.644.73
Filing Date Shares Outstanding29.08M10.61M9.26M
Total Common Shares Outstanding10.96M10.61M9.26M
Working Capital58.24M98.12M45.55M
Book Value Per Share-22.90-20.45-17.03
Tangible Book Value-251.07M-217.08M-157.73M
Tangible Book Value Per Share-22.90-20.45-17.03
Machinery10.75M9.14M7.59M
Construction In Progress11.04M8.64M1.94M
Leasehold Improvements5.65M5.65M5.65M

Cash flow statement

Fiscal year January - December; amounts in USD.

TTMFY2025FY2024
Net Income-66.84M-62.06M-48.56M
Depreciation & Amortization4.13M3.96M3.51M
Loss (Gain) From Sale of Investments-844.00K-53.00K-1.96M
Stock-Based Compensation3.78M2.52M2.71M
Other Operating Activities2.81M4.55M-496.00K
Change in Accounts Payable2.90M1.79M-304.00K
Change in Other Net Operating Assets-2.67M-3.55M935.00K
Operating Cash Flow-56.73M-52.85M-44.16M
Capital Expenditures-9.78M-9.69M-2.58M
Investment in Securities-36.40M13.89M28.21M
Other Investing Activities-5.00M
Investing Cash Flow-46.17M4.20M20.63M
Issuance of Common Stock245.00K173.00K467.00K
Other Financing Activities-1.08M-271.00K-10.00K
Financing Cash Flow114.78M115.53M457.00K
Net Cash Flow11.88M66.88M-23.07M
Free Cash Flow-66.51M-62.54M-46.75M
Free Cash Flow Per Share-6.26-6.06-5.05
Levered Free Cash Flow-39.94M
Unlevered Free Cash Flow-39.94M
Change in Working Capital227.00K-1.76M631.00K

Ratios

Fiscal year January - December; amounts in USD.

TTMFY2025FY2024
Market Capitalization379.18M
Enterprise Value316.58M
Debt / Equity Ratio0.110.090.21
Net Debt / Equity Ratio-0.71-0.82-0.67
Net Debt / EBITDA Ratio0.961.730.84
Net Debt / FCF Ratio0.941.590.94
Quick Ratio4.437.764.11
Current Ratio4.567.884.25
Return on Equity (ROE)-66.20%
Return on Assets (ROA)-31.70%
Return on Capital Employed (ROCE)-70.90%-45.80%-70.20%
Buyback Yield / Dilution-11.41%